Immunotherapy in Ovarian Cancer:(IGWHC)-Lupine Publishers



Ovarian cancer ranks fifth with a 5-year survival of 40% for patients with advanced disease and remains the most lethal gynecologic malignancy among women [1]. Most patients with advanced disease undergo aggressive frontline treatments with surgery and adjuvant chemotherapy; however, 80% of patients ultimately recur within few months and develop chemoresistant disease [2]. Advances in traditional treatment regimens and addition bevacizumab as a targeted therapy have shown promising results with improved progression-free survival but overall survival rates still remains the unaltered.


For more Lupine Publishers Open Access Journals Please visit our website: http://www.lupinepublishers.com/

For more Healthcare Open Access Journal articles Please Click Here: http://www.lupinepublishers.com/gynecology-women-health-journal/

Comments

Popular posts from this blog

What is the role of Editors in Lupine Publishers?

Journal of Obstetrics and Gynaecology-Lupine Publishers

Lupine Publishers-Journal of Women's Health Care